

Supplementary Online Content

Katz MHG, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. *JAMA Surg*. Published online June 8, 2016.
doi:10.1001/jamasurg.2016.1137.

eTable. Studies of FOLFIRINOX for borderline resectable and/or locally advanced pancreatic cancer published 2013-2015

This supplementary material has been provided by the authors to give readers additional information about their work.

Supplemental Table. Studies of FOLFIRINOX for borderline resectable and/or locally advanced pancreatic cancer published 2013-2015

Study	Type of study	Staging system	No. of patients by stage	Cycles FFX, median (range)	CXRT	No. of patients with grade 3/4 AEs N (%)	No. of patients resected ^a N (%)	RO ^b , no. of patients (%)	VR ^b , no. of patients (%)	OS ^a
Sadot [28]	Retrospective, single center	NCCN [33]	III, 101	6 (1-20)	Variabl e	14 (14)	31 (31)	16 (52)	8 (26)	Median OS 25 mo
Christians [29]	Retrospective, single center	MCW [29]	BLR, 18	4 (3-8)	Variabl e	9 (75)*	12 (67)	12 (100)	10 (83)	NR
Mahaseth [30]	Retrospective, single center	Not specified	Met, 36 III, 20 II, 4	3 (1-10)	Variabl e	24 (40)	6 (25)	5 (83)	NR	Median OS 17.8 mo
Boone [31]	Retrospective, single center	AHPBA/SSO/SSAT [11]	Unresectable, 10 BLR, 11	5 ^o (1->7)	Variabl e	NR	9 (43)	7 (78)	5 (56)	NR
Tinchon [32]	Retrospective, single center	AHPBA/SSO/SSAT [11]	Met, 2 BLR, 10	NR	None	5 (42)	8 (80)	NR	4 (40)	NR
Current study	Prospective, multicenter	Intergroup [7]	BLR, 22	4	50.4 Gy + cape	14 (64)	15 (68)	14 (93)	12 (80)	Median OS 21.7 mo

Abbreviations: FFX, modified FOLFIRINOX; CXRT, chemoradiation; AEs, adverse events; VR, vascular resection; OS, overall survival; NCCN, National Comprehensive Cancer Network; MCW, Medical College of Wisconsin; AHPBA, American Hepatopancreatobiliary Association; SSO, Society of Surgical Oncology; SSAT, Society

for Surgery of the Alimentary Tract; BLR, borderline resectable; Met, metastatic; NR, not reported; cape, capecitabine.

^aOf patients with localized disease.

^bOf patients who underwent resection.

*Of 12 patients for whom data was available.

^φMean